{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-113467","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.393227+00:00","generated_at":"2026-05-28T22:41:35.151105+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA","bullets":["DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.","Participants in remission increased from 0% at baseline to 16.67% at week 8.","Pain levels dropped from 75% reporting negative result to 50%; morning stiffness from 75% to 41.67%.","91.7% of participants would recommend Raphael's Formula to others with RA; 83.3% willing to continue use.","Blood biomarkers showed no statistically significant changes, but overall symptom management improved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-113467","json":"https://secwatch.observer/filing/0001213900-24-113467.json","markdown":"https://secwatch.observer/filing/0001213900-24-113467.md","text":"https://secwatch.observer/filing/0001213900-24-113467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/0001213900-24-113467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/ea0226291-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:41:35.151105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}